Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708257 | 0.81 | MAOA (0.49) | ESRRANOTUMSPRCA1CA2 | |
| SCHEMBL71218 | 0.79 | ESRRA (0.47) | HCAR2ESRRANOTUMSPRCA1 | |
| SCHEMBL69876 | 0.78 | ESRRA (0.62) | ESRRANOTUMSPRCA1CA2 | |
| SCHEMBL28801446 | 0.76 | ESRRA (0.60) | ESRRANOTUMSPRCA1CA2 | |
| SCHEMBL12571550 | 0.75 | HCAR2 (0.43) | HCAR2 | |
| SCHEMBL31162164 | 0.75 | DDX3X (0.44) | CA1CA2CA4CA9 | |
| SCHEMBL27877288 | 0.75 | ESRRA (0.57) | ESRRACA1CA2CA4CA9 | |
| SCHEMBL2330243 | 0.73 | CA1 (0.57) | ESRRANOTUMCA1CA2CA4 | |
| SCHEMBL11902351 | 0.73 | CA1 (0.57) | ESRRANOTUMCA1CA2CA4 | |
| SCHEMBL3477570 | 0.73 | CA1 (0.57) | ESRRANOTUMCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | HCAR2 274/4885ESRRA 1985/4885NOTUM 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.